Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction

• DOI: 10.1016/j.jchf.2021.11.006
• Publication Date: 2022-02-28T20:18:47Z
• Authors: Scott D. Solomon; Muthiah Vaduganathan; Brian L. Claggett; Rudolf A. de Boer; David DeMets; Adrian F. Hernandez; Silvio E. Inzucchi; Mikhail N. Kosiborod; Carolyn S.P. Lam; Felipe Martinez; Sanjiv J. Shah; Jan Belohlavek; Chern-En Chiang; C. Jan Willem Bor...; Josep Comin-Colet; Dan Dobreanu; Jaroslaw Drozdz; James C. Fang; Marco Antonio Alc...; Waleed Al Habeeb; Yaling Han; Jose Walter Cabre...; Stefan P. Janssens; Tsvetana Katova; Masafumi Kitakaze; Bela Merkely; Eileen O’Meara; Jose Francisco Ke...; Sergey N. Teresch...; Jorge Thierer; Orly Vardeny; Subodh Verma; Pham Nguyen Vinh; Ulrica Wilderäng; Natalia Zaozerska; Daniel Lindholm; Magnus Petersson; John J.V. McMurray
• Keywords: Dapagliflozin

This report describes the baseline clinical profiles and management of DELIVER (Dapagliflozin Evaluation to Improve Lives Patients With Preserved Ejection Fraction Heart Failure) trial participants how these compare with those in other contemporary heart failure preserved ejection fraction trials.The was designed evaluate effects sodium-glucose cotransporter-2 inhibitor dapagliflozin on cardiovascular death, (HF) hospitalization, or urgent HF visits patients mildly reduced left ventricular (LVEF).Adults symptomatic LVEF >40%, without type 2 diabetes mellitus, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, evidence structural disease were randomized 10 mg once daily matching placebo.A total 6,263 (mean age: 72 ± years; 44% women; 45% mellitus; body mass index ≥30 kg/m2; 57% history atrial fibrillation flutter). Most had New York Association functional class II symptoms (75%). Baseline mean 54.2 8.8% median NT-proBNP 1,399 pg/mL (IQR: 962 2,210 pg/mL) for fibrillation/flutter compared 716 469 1,281 who not. both hospitalized ambulatory settings enrolled, including 10% enrolled in-hospital within 30 days a hospitalization HF. Eighteen percent improved LVEF.DELIVER is largest broadest this population date high-risk, well-treated LVEF. Failure [NCT03619213]).